Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer.
PSMA
neovasculature
ovarian cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
31 Mar 2022
31 Mar 2022
Historique:
received:
22
02
2022
revised:
22
03
2022
accepted:
28
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) is present in the tumor-associated neovasculature of many cancer types. Current data in ovarian cancer are limited and controversial; thus, the aim of this study was to investigate PSMA expression in a larger and homogenous patient cohort. This might lead to further studies investigating the use of imaging and therapeutic modalities targeting PSMA. Eighty patients with advanced stage high-grade serous ovarian cancers were included. Using immunohistochemistry, PSMA and CD31, a marker for endothelial cells, were examined in whole tissue sections. Percentage and intensity of PSMA expression were determined in the neovasculature. Expression levels were correlated with clinicopathological parameters and survival. Low (≤10%), medium (20-80%), and high (≥90%) PSMA expression was found in 14, 46, and 20 ovarian cancer samples, respectively. PSMA expression was confined to tumor-associated neovasculature and significantly correlated with progression-free (HR 2.24, 95% CI 1.32-3.82,
Identifiants
pubmed: 35455669
pii: jpm12040551
doi: 10.3390/jpm12040551
pmc: PMC9025859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Scientific Fund of the Mayor of the City of Vienna
ID : 19045
Références
Clin Transl Gastroenterol. 2019 May 22;10(5):1-7
pubmed: 31116141
Cancer Imaging. 2011 Aug 24;11:123-39
pubmed: 21865109
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
J Urol. 2018 Feb;199(2):370-377
pubmed: 28827104
J Pers Med. 2021 Jun 30;11(7):
pubmed: 34209106
Am J Clin Pathol. 2014 Nov;142(5):629-33
pubmed: 25319977
J Urol. 2021 Jul;206(1):52-61
pubmed: 33634707
APMIS. 2014 Jun;122(6):482-9
pubmed: 24304465
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
EJNMMI Res. 2021 Feb 9;11(1):11
pubmed: 33559764
Angiogenesis. 2016 Oct;19(4):487-500
pubmed: 27387982
Mod Pathol. 2012 Aug;25(8):1079-85
pubmed: 22460809
Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):271-276
pubmed: 26862945
Cancer Res. 1993 Jan 15;53(2):227-30
pubmed: 8417812
Sci Rep. 2021 Jul 22;11(1):15000
pubmed: 34294841
Eur Radiol. 2021 Apr;31(4):2199-2208
pubmed: 33001304
Am J Physiol Cell Physiol. 2005 May;288(5):C975-81
pubmed: 15840561
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368
pubmed: 34120192
EJNMMI Res. 2019 Oct 15;9(1):93
pubmed: 31617002
Int J Mol Sci. 2017 Sep 14;18(9):
pubmed: 28906427
Virchows Arch. 2007 Oct;451(4):763-9
pubmed: 17674041
BMC Cancer. 2019 Jun 14;19(1):584
pubmed: 31200683